{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:31:16Z","timestamp":1788201076919,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Institutes of Health, National Center for Advancing Translational Sciences","award":["UL1TR002529"],"award-info":[{"award-number":["UL1TR002529"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00228-022-03346-7","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T11:25:00Z","timestamp":1654255500000},"page":"1217-1225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical non-effectiveness of clopidogrel use for peripheral artery disease in patients with CYP2C19 polymorphisms: a systematic review"],"prefix":"10.1007","volume":"78","author":[{"given":"Shu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonkyeong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirly","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan H.","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hsuan","family":"Lo-Ciganic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Eadon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titus","family":"Schleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Whipple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khoa Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"3346_CR1","doi-asserted-by":"publisher","first-page":"8295054","DOI":"10.1155\/2019\/8295054","volume":"2019","author":"R Bauersachs","year":"2019","unstructured":"Bauersachs R et al (2019) Burden of coronary artery disease and peripheral artery disease: a literature review. Cardiovasc Ther 2019:8295054","journal-title":"Cardiovasc Ther"},{"issue":"22","key":"3346_CR2","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1001\/archinte.167.22.2482","volume":"167","author":"HHH Feringa","year":"2007","unstructured":"Feringa HHH et al (2007) A prognostic risk index for long-term mortality in patients with peripheral arterial disease. Arch Intern Med 167(22):2482\u20132489","journal-title":"Arch Intern Med"},{"key":"3346_CR3","unstructured":"CDC. Peripheral Arterial Disease (PAD). Septmber 2, 2021]; Available from: https:\/\/www.cdc.gov\/heartdisease\/PAD.htm"},{"issue":"12","key":"3346_CR4","first-page":"e686","volume":"135","author":"MD Gerhard-Herman","year":"2017","unstructured":"Gerhard-Herman MD et al (2017) 2016 AHA\/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 135(12):e686\u2013e725","journal-title":"Circulation"},{"issue":"4","key":"3346_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1055\/s-0032-1330232","volume":"21","author":"TF Whayne","year":"2012","unstructured":"Whayne TF (2012) A review of the role of anticoagulation in the treatment of peripheral arterial disease. Int J Angiol 21(4):187\u2013194","journal-title":"Int J Angiol"},{"key":"3346_CR6","unstructured":"Kane SP (2021)\u00a0Clopidogrel. September 12, 2021 [cited 2022 Feburary 28]; Version 21.2:[Available from: https:\/\/clincalc.com\/DrugStats\/Drugs\/Clopidogrel"},{"key":"3346_CR7","unstructured":"FDA (2017)\u00a0FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. 2017; Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-review-finds-long-term-treatment-blood-thinning-medicine-plavix"},{"issue":"3","key":"3346_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.2013.105","volume":"94","author":"SA Scott","year":"2013","unstructured":"Scott SA et al (2013) Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94(3):317\u2013323","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"3346_CR9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/CIR.0b013e3181ee08ed","volume":"122","author":"DR Holmes","year":"2010","unstructured":"Holmes DR et al (2010) ACCF\/AHA clopidogrel clinical alert: approaches to the FDA Boxed Warning. Circulation 122(5):537\u2013557","journal-title":"Circulation"},{"issue":"3","key":"3346_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jmoldx.2018.01.011","volume":"20","author":"VM Pratt","year":"2018","unstructured":"Pratt VM et al (2018) Recommendations for clinical CYP2C19 genotyping allele selection: a report of the association for molecular pathology. J Mol Diagn 20(3):269\u2013276","journal-title":"J Mol Diagn"},{"key":"3346_CR11","unstructured":"Electronic Code of Federal Regulations Part 493\u2014Laboratory Requirements. Available from: https:\/\/www.ecfr.gov\/current\/title-42\/chapter-IV\/subchapter-G\/part-493"},{"key":"3346_CR12","unstructured":"Clinical Pharmacogenetics Implementation Consortium Guidelines. Available from: https:\/\/cpicpgx.org\/guidelines\/"},{"issue":"11","key":"3346_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784","journal-title":"Ann Intern Med"},{"key":"3346_CR14","unstructured":"Higgins JPT et al (2021)\u00a0Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). 2021; Available from: www.training.cochrane.org\/handbook"},{"key":"3346_CR15","unstructured":"Veritas Health Innovation. Covidence systematic review software. Available from: www.covidence.org"},{"key":"3346_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"issue":"1","key":"3346_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"CK-L Lo","year":"2014","unstructured":"Lo CK-L, Mertz D, Loeb M (2014) Newcastle-Ottawa Scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol 14(1):45","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"3346_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13643-019-1172-8","volume":"8","author":"K Farrah","year":"2019","unstructured":"Farrah K et al (2019) Risk of bias tools in systematic reviews of health interventions: an analysis of PROSPERO-registered protocols. Syst Rev 8(1):280","journal-title":"Syst Rev"},{"key":"3346_CR19","unstructured":"Sterne JAC, Higgins JPT, Elbers RG, Reeves BC and the development group for ROBINSI (2016) Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I): detailed guidance. October 20, 2016 [cited 2021 September 3]; Available from:\u00a0http:\/\/www.riskofbias.info"},{"issue":"4","key":"3346_CR20","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jvs.2014.03.293","volume":"60","author":"B Guo","year":"2014","unstructured":"Guo B et al (2014) Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. J Vasc Surg 60(4):993\u20131001","journal-title":"J Vasc Surg"},{"issue":"6","key":"3346_CR21","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00270-013-0577-3","volume":"36","author":"G Pastromas","year":"2013","unstructured":"Pastromas G et al (2013) Clopidogrel responsiveness in patients undergoing peripheral angioplasty. Cardiovasc Intervent Radiol 36(6):1493\u20131499","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"12","key":"3346_CR22","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2217\/pgs-2016-0056","volume":"17","author":"X D\u00edaz-Villamar\u00edn","year":"2016","unstructured":"D\u00edaz-Villamar\u00edn X et al (2016) Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty. Pharmacogenomics 17(12):1327\u20131338","journal-title":"Pharmacogenomics"},{"issue":"3","key":"3346_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ejvs.2019.02.011","volume":"58","author":"J Lee","year":"2019","unstructured":"Lee J et al (2019) CYP2C19 Polymorphism is associated with amputation rates in patients taking clopidogrel after endovascular intervention for critical limb ischaemia. Eur J Vasc Endovasc Surg 58(3):373\u2013382","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"5","key":"3346_CR24","doi-asserted-by":"publisher","first-page":"641","DOI":"10.4065\/81.5.641","volume":"81","author":"GW Stone","year":"2006","unstructured":"Stone GW, Aronow HD (2006) Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy. Mayo Clin Proc 81(5):641\u2013652","journal-title":"Mayo Clin Proc"},{"issue":"24","key":"3346_CR25","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1001\/jama.2011.1880","volume":"306","author":"MV Holmes","year":"2011","unstructured":"Holmes MV et al (2011) CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 306(24):2704\u20132714","journal-title":"JAMA"},{"issue":"7","key":"3346_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104877","volume":"29","author":"V Alakbarzade","year":"2020","unstructured":"Alakbarzade V et al (2020) High on-clopidogrel platelet reactivity in ischaemic stroke or transient ischaemic attack: systematic review and meta-analysis. J Stroke Cerebrovasc Dis 29(7):104877","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"12","key":"3346_CR27","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/jcph.769","volume":"56","author":"NF Ford","year":"2016","unstructured":"Ford NF (2016) The metabolism of clopidogrel: CYP2C19 is a minor pathway. J Clin Pharmacol 56(12):1474\u20131483","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"3346_CR28","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/cts.12926","volume":"14","author":"KA Nguyen","year":"2021","unstructured":"Nguyen KA et al (2021) Risk factors for bleeding and clinical ineffectiveness associated with clopidogrel therapy: a comprehensive meta-analysis. Clin Transl Sci 14(2):645\u2013655","journal-title":"Clin Transl Sci"},{"issue":"22","key":"3346_CR29","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.jacc.2011.11.068","volume":"59","author":"MJ Price","year":"2012","unstructured":"Price MJ et al (2012) Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol 59(22):1928\u20131937","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3346_CR30","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ahj.2010.06.039","volume":"160","author":"KA Tiroch","year":"2010","unstructured":"Tiroch KA et al (2010) Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 160(3):506\u2013512","journal-title":"Am Heart J"},{"issue":"4","key":"3346_CR31","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","volume":"121","author":"D Sibbing","year":"2010","unstructured":"Sibbing D et al (2010) Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121(4):512\u2013518","journal-title":"Circulation"},{"issue":"18","key":"3346_CR32","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","volume":"363","author":"G Par\u00e9","year":"2010","unstructured":"Par\u00e9 G et al (2010) Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 363(18):1704\u20131714","journal-title":"N Engl J Med"},{"issue":"9749","key":"3346_CR33","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","volume":"376","author":"L Wallentin","year":"2010","unstructured":"Wallentin L et al (2010) Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749):1320\u20131328","journal-title":"Lancet"},{"issue":"25","key":"3346_CR34","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","volume":"57","author":"G Campo","year":"2011","unstructured":"Campo G et al (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57(25):2474\u20132483","journal-title":"J Am Coll Cardiol"},{"key":"3346_CR35","unstructured":"CPIC. CPIC guidelines. 2021; Available from: https:\/\/cpicpgx.org\/guidelines\/"},{"issue":"1","key":"3346_CR36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12967-018-1469-8","volume":"16","author":"LH Cavallari","year":"2018","unstructured":"Cavallari LH et al (2018) Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. J Transl Med 16(1):92","journal-title":"J Transl Med"},{"issue":"5","key":"3346_CR37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00228-020-03050-4","volume":"77","author":"S Russmann","year":"2021","unstructured":"Russmann S et al (2021) Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice. Eur J Clin Pharmacol 77(5):709\u2013716","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"3346_CR38","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2217\/pgs-2018-0013","volume":"19","author":"TO Bergmeijer","year":"2018","unstructured":"Bergmeijer TO et al (2018) Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy. Pharmacogenomics 19(7):621\u2013628","journal-title":"Pharmacogenomics"},{"issue":"2","key":"3346_CR39","doi-asserted-by":"publisher","first-page":"946","DOI":"10.18549\/PharmPract.2017.02.946","volume":"15","author":"SG Johnson","year":"2017","unstructured":"Johnson SG et al (2017) Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system. Pharm Pract (Granada) 15(2):946","journal-title":"Pharm Pract (Granada)"},{"issue":"5","key":"3346_CR40","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1160\/TH13-09-0767","volume":"111","author":"D Erlinge","year":"2014","unstructured":"Erlinge D et al (2014) Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease. Thromb Haemost 111(5):943\u2013950","journal-title":"Thromb Haemost"},{"issue":"6","key":"3346_CR41","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/ijlh.12416","volume":"37","author":"V Arya","year":"2015","unstructured":"Arya V et al (2015) Association of CYP2C19, CYP3A5 and GPIIb\/IIIa gene polymorphisms with aspirin and clopidogrel resistance in a cohort of Indian patients with coronary artery disease. Int J Lab Hematol 37(6):809\u2013818","journal-title":"Int J Lab Hematol"},{"key":"3346_CR42","unstructured":"Dean L (2012)\u00a0Clopidogrel Therapy and CYP2C19 Genotype, in Medical genetics summaries, Pratt VM et al Editors\u00a02012, National Center for Biotechnology Information (US): Bethesda (MD)"},{"issue":"8","key":"3346_CR43","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jama.2020.12443","volume":"324","author":"NL Pereira","year":"2020","unstructured":"Pereira NL et al (2020) Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA 324(8):761\u2013771","journal-title":"JAMA"},{"key":"3346_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ijcard.2021.04.029","volume":"334","author":"DMF Claassens","year":"2021","unstructured":"Claassens DMF et al (2021) Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: a pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients. Int J Cardiol 334:10\u201317","journal-title":"Int J Cardiol"},{"issue":"8","key":"3346_CR45","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/s41591-019-0492-5","volume":"25","author":"D Klarin","year":"2019","unstructured":"Klarin D et al (2019) Genome-wide association study of peripheral artery disease in the Million Veteran Program. Nat Med 25(8):1274\u20131279","journal-title":"Nat Med"},{"issue":"5","key":"3346_CR46","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/ICU.0000000000000085","volume":"25","author":"JE Capasso","year":"2014","unstructured":"Capasso JE (2014) The cost of genetic testing for ocular disease: who pays? Curr Opin Ophthalmol 25(5):394\u2013399","journal-title":"Curr Opin Ophthalmol"},{"issue":"8","key":"3346_CR47","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/s41591-019-0534-z","volume":"25","author":"JC B\u00e9lisle-Pipon","year":"2019","unstructured":"B\u00e9lisle-Pipon JC et al (2019) Genetic testing, insurance discrimination and medical research: what the United States can learn from peer countries. Nat Med 25(8):1198\u20131204","journal-title":"Nat Med"},{"issue":"3","key":"3346_CR48","first-page":"e18","volume":"145","author":"JS Lawton","year":"2022","unstructured":"Lawton JS et al (2022) 2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(3):e18\u2013e114","journal-title":"Circulation"},{"issue":"6","key":"3346_CR49","first-page":"362","volume":"99","author":"JM Firnhaber","year":"2019","unstructured":"Firnhaber JM, Powell CS (2019) Lower extremity peripheral artery disease: diagnosis and treatment. Am Fam Physician 99(6):362\u2013369","journal-title":"Am Fam Physician"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03346-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03346-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03346-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T07:07:31Z","timestamp":1657782451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03346-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["3346"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03346-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"22 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors, and do not necessarily reflect the views of the funding agencies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}